Le profil de tolérance des sels de platine dans le traitement de carcinome bronchique (expérience du service de pneumo-phtisiologie du chu de Sétif)

Abstract

Bronchopulmonary cancer is a public health problem, it is the 1 st most frequent cancer in the world in terms of incidence and mortality of men. In Algeria, the incidence is higher for men than women. The goal of our study was to evaluate the tolerance profile of platinum salts in the treatment of bronchial carcinoma at the level of the Pneumo-Phtisiology Department of Setif(medical oncology unit of Setif) . It is a descriptive, cross-sectional and monocentric study of all cases of bronchial carcinoma treated with platinum salts, included 19 patients , over a period of time from 03/01/ 2022 to 24/04/ 2022. The average age of diagnosis was 58.52 years, the sex ratio was (2.8), active smoking was 52.63% of cases and passive smoking in 73.68% of cases, only 21.05% were weaned, 47.37% of patients were exposed to toxic agents as part of an occupational exposure, the discovery was symptomatic in 84.2% of cases, dominated by chest pain 24%, 73.68% of cases with a lymph node metastasis, All patients in our population were put on platinum salts as first line, the most observed side effects are hematological disorders (anemia 36.84%), digestive disorders (Diarrhea 42.11% V 73.68%) and skin rash (52.63%), renal toxicity (36.84%), asthenia (63.16%), the management of side effects was a symptomatic treatment for the majority of patients, the quality of life of 63.16% of patients was declared improved. The discrepancy between our results, the literature data and the different studies could be related to the small number of our population which requires studies with a broad spectrum